TransThera Sciences (Nanjing), Inc.
Quick facts
Phase 3 pipeline
- TT-00420 (tinengotinib) · Oncology
Tinengotinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis.
Phase 2 pipeline
Phase 1 pipeline
- Combination Product: Atezolizumab
- Combination Product: Nab-Paclitaxel
- TT-00434
- TT-00920
- TT-00973-MS tablets treatment
- TT-01488
- TT-01488 Tablets
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: